Graft aberrant hepatic arteries in deceased donor liver transplantation: The “one liver, one artery” approach

Riccardo Pravisani, Ailton Sepulveda, Lorenzo Cocchi, Estrella Mello, Francois Cauchy, Safi Dokmak, Olivier Farges, Francois Durand, Emmanuel Weiss, Federica Dondero, Mickaël Lesurtel – 23 June 2022 – In liver transplantation (LT), graft aberrant hepatic arteries (aHAs) frequently require complex arterial reconstructions, potentially increasing the risk of post‐operative complications. However, intrahepatic hilar arterial shunts are physiologically present and may allow selective aHA ligation.

Hepatitis C is associated with more adverse pregnancy outcomes than hepatitis B: A 7‐year national inpatient sample study

Bing Chen, Yichen Wang, Marcia Lange, Tatyana Kushner – 23 June 2022 – Prior international studies have shown mixed results regarding the association of hepatitis B and hepatitis C with adverse pregnancy outcomes. We performed an updated evaluation of the prevalence of associated adverse pregnancy outcomes and evaluated trends over time of diagnosis of chronic hepatitis B (HBV) and chronic hepatitis C (HCV) in pregnant women in a national database. All pregnant women with HBV and HCV were identified from the National Inpatient Sample database 2012 to 2018.

Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis

Archana Vijayakumar, Ayse Okesli‐Armlovich, Ting Wang, Isabel Olson, Minji Seung, Saritha Kusam, David Hollenback, Sangeetha Mahadevan, Bruno Marchand, Maria Toteva, David G. Breckenridge, James L. Trevaskis, Jamie Bates – 22 June 2022 – Dysregulated hepatocyte lipid metabolism is a hallmark of hepatic lipotoxicity and contributes to the pathogenesis of nonalcoholic steatohepatitis (NASH).

Implementation of a controlled human infection model for evaluation of HCV vaccine candidates

Eleanor Barnes, Graham S. Cooke, Georg M. Lauer, Raymond T. Chung – 22 June 2022 – Hepatitis C virus (HCV) remains a major global health concern. Directly acting antiviral (DAA) drugs have transformed the treatment of HCV. However, it has become clear that, without an effective HCV vaccine, it will not be possible to meet the World Health Organization targets of HCV viral elimination. Promising new vaccine technologies that generate high magnitude antiviral T and B cell immune responses and significant new funding have recently become available, stimulating the HCV vaccine pipeline.

Low‐dose aspirin confers protection against acute cellular allograft rejection after primary liver transplantation

Christian E. Oberkofler, Dimitri A. Raptis, Philip C. Müller, Richard X. Sousa da Silva, Kuno Lehmann, Takahiro Ito, Timothy Owen, Joerg‐Matthias Pollok, Alessandro Parente, Andrea Schlegel, Peregrina Peralta, Erin Winter, Markus Selzner, Margot Fodor, Manuel Maglione, Manuel Jaklitsch, Hugo P. Marques, Mariana Chavez‐Villa, Alan Contreras, Philipp Kron, Peter Lodge, Scott Alford, Abbas Rana, Paolo Magistri, Fabrizio Di Benedetto, Bethany Johnson, Varvara Kirchner, Francis Bauldrick, Karim J. Halazun, Omid Ghamarnedjad, Arianeb Mehrabi, Samanta Teixeira Basto, Eduardo S. M.

Apolipoprotein F is reduced in humans with steatosis and controls plasma triglyceride‐rich lipoprotein metabolism

Audrey Deprince, Nathalie Hennuyer, Sander Kooijman, Amanda C. M. Pronk, Eric Baugé, Viktor Lienard, An Verrijken, Eveline Dirinck, Luisa Vonghia, Eloïse Woitrain, Niels J. Kloosterhuis, Eléonore Marez, Pauline Jacquemain, Justina C. Wolters, Fanny Lalloyer, Delphine Eberlé, Sandrine Quemener, Emmanuelle Vallez, Anne Tailleux, Mostafa Kouach, Jean‐Francois Goossens, Violeta Raverdy, Bruno Derudas, Jan Albert Kuivenhoven, Mikaël Croyal, Bart Sluis, Sven Francque, François Pattou, Patrick C. N. Rensen, Bart Staels, Joel T. Haas – 22 June 2022

Subscribe to